A securities class action has been filed against Infinity Pharmaceuticals, Inc. (INFI) on behalf of persons or entities who purchased or otherwise acquired Infinity securities between January 5, 2022 through July 24, 2023.  This case has been filed in the USDC – MA.

The complaint alleges that during the Class Period, Defendants materially misled the investing public, thereby inflating the price of Infinity’s securities, by publicly issuing false and/or misleading statements and/or omitting to disclose material facts necessary to make Defendants’ statements, as set forth herein, not false and/or misleading. Said statements and omissions were materially false and/or misleading in that they failed to disclose material adverse information and/or misrepresented the truth about Infinity’s business, operations, and prospects as alleged herein.